Form 4: Neumora Therapeutics Director Maykin Ho Reports Acquisition and Disposal of Shares

Director Maykin Ho reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Summary

• Maykin Ho, a director of Neumora Therapeutics, reported transactions involving the company's securities on June 13, 2024.
• Ho acquired 20,100 restricted stock units (RSUs) and disposed of 20,100 shares of common stock.
• Additionally, Ho acquired options to purchase 28,571 shares of common stock at an exercise price of $9.95.
• The RSUs and stock options vest on the earlier of June 13, 2025, or immediately prior to the next Annual Meeting following June 13, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock ownership changes.

Future Outlook

The vesting of the RSUs and stock options is tied to future events (either a specific date or the next Annual Meeting), indicating a continued relationship between the director and the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a company director.

Key Dates